Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial

Background Given the success of checkpoint inhibitor therapy in the advanced Merkel cell carcinoma (MCC) setting, there is interest in exploring immunotherapy as a neoadjuvant approach. We report the primary results of a neoadjuvant study of lenvatinib plus pembrolizumab in resectable MCC.Methods In...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Joseph Markowitz, Amod Sarnaik, Ahmad A Tarhini, Zeynep Eroglu, Evan J Wuthrick, Andrew S Brohl, Nikhil I Khushalani, Rogerio I Neves, Vernon K Sondak, Wenyi Fan, Younchul Kim, Kenneth Y Tsai, Matthew C Perez, Justin Martin, Lymon Sneed, Michael Harrington, Ricardo J Gonzalez, Jonathan S Zager, C Wayne Cruse
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMJ Publishing Group 2026-01-01
Edice:	Journal for ImmunoTherapy of Cancer
On-line přístup:	https://jitc.bmj.com/content/14/1/e013939.full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!